Navigation Links
Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
Date:8/19/2008

SEATTLE and OSLO, Norway, Aug. 19 /PRNewswire/ -- Omeros Corporation, a Seattle-based clinical-stage biopharmaceutical company, and Affitech AS, a Norwegian human antibody therapeutics company, today announced that they have entered into an agreement for the discovery and development of fully human antibodies for Omeros' MASP-2 program. MASP-2, or mannan-binding lectin-associated serine protease-2, mediates activation of the complement system via the lectin pathway and is linked to multiple potential indications across a wide range of inflammatory diseases including macular degeneration, rheumatoid arthritis, transplant rejection and cardiovascular and renal ischemia-reperfusion injury.

"This agreement marks an important milestone in our MASP-2 program, and ensures that Omeros can access high-affinity, fully human antibodies against MASP-2," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "We are impressed by Affitech's technology, track record and personnel, and look forward to our collaboration."

Under this collaboration, Omeros, based on its exclusive intellectual property position, will continue to advance the development of its MASP-2 program. Affitech will apply its expansive human antibody libraries and proprietary antibody discovery and screening technologies, including its AffiScreen(TM) platform and engineering methods, to generate fully human MASP-2 antibodies for Omeros. Financial terms include a technology access fee, a series of milestone payments, and royalties on net sales, payable by Omeros. No further terms of the agreement were disclosed.

"We are excited about this collaboration with Omeros," said Martin Welschof, Ph.D., CEO of Affitech. "Omeros' proprietary MASP-2 program is focused on a target with broad commercial applications, and provides Affitech the opportunity to apply our expertise, human antibody library and screening platform to a non-cancer disease field. We believe that our proven technology, to
'/>"/>

SOURCE Affitech AS; Omeros Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Omeros Appoints David A. Mann to its Board of Directors
2. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
3. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
4. American Laser Centers Opens Three Minneapolis-St. Paul Area Clinics
5. Chromos enters into an Arrangement Agreement
6. NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
7. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
8. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
9. Stem Cell Transplantation Research at The Cancer Center at Hackensack University Medical Center Aims to Develop Designer Transplants
10. Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases
11. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
(Date:12/2/2009)NEW YORK, Dec. 2 Reportlinker.com announces that a new market research report is available in its catalogue: ,, Drug Discovery Technologies - A Global Update of Market Trends & Opportunities ,,
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor of infant and children,s formul
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Libreville International Conference 2-3 June 2010 2Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2
...Nov. 20 New Generation Biofuels Inc. (Nasdaq: ...Test Burn Agreement with Progress Energy Florida (...el technology in utility boiler applications. , ...ls to supply its biofuel for a test program that w...Florida,s Bartow Plant in St. Petersburg. The test...
...ov. 20 SuperGen, Inc.,(Nasdaq: SUPG ), a pharma...velopment of novel cancer therapies, today announc...ical trials with SGI-1776, an inhibitor of Pim,kin...l New Drug Application,("IND") triggers a $5.2 mil...of Montigen Pharmaceuticals, Inc. The milestone p...
... Celsis International plc,(LSE: CEL.L), the global...,industry, today announced the launch of RapiScree...Innovate -- the company,s proven rapid microbial,s...apid screening test kit,extends the Celsis Innovat...,Heat Treated (UHT) and Extended Shelf Life (ESL) ...
Other Biology Technology:New Generation Biofuels Announces Test Burn Agreement With Progress Energy Florida 2New Generation Biofuels Announces Test Burn Agreement With Progress Energy Florida 3SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor 2SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor 3Celsis Launches RapiScreen(TM) Beverage Microbial Screening System 2
(Date:12/2/2009)PHILADELPHIA Children exposed to secondhand cigarette smoke have an increased risk of developing lung cancer in adulthood, even if they never smoked. , Results of this study are published in Cance
(Date:12/2/2009)PHILADELPHIA New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for ot
(Date:12/2/2009)PHILADELPHIA People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smo
Breaking Biology News(10 mins):Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Cigarette smoking increases colorectal cancer risk 2Increased nicotine levels detected in those who light-up earlier 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 1Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 3Bellicum Pharmaceuticals Announces 244 5 Million in New Funding 5724 1Bellicum Pharmaceuticals Announces 244 5 Million in New Funding 5724 2RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products 14602 1RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products 14602 2RB Rubber Introduces Environmentally Friendly Antimicrobial Rubber Flooring Products 14602 3
... (April 6, 2009) Cell Press, an imprint of Elsevi...ll , as well as Current Biology and The America... Special Library Association,s (SLA) Top 100 Journ... The Top 100 list is compiled by the 680-plus mem...ision (DBIO) on the most influential journals in b...
...electric ion propulsion system has been switched o...another crucial milestone in the satellite,s post-...,s ultra-sensitive gravity measurements depends on...d. The push from the thruster must be just enough ...d by the few wisps of atmosphere at GOCE,s orbital...
...nt systems for splitting water into hydrogen and o...ant challenges facing science today, underpinning ...stainable fuel. But man-made systems that exist to...nal use of sacrificial chemical agents. In this co... by which water splitting can take place. , Now, ...
Other Biology News:Three prominent Cell Press journals named among the 100 most influential journals in past 100 years 2GOCE's electric ion propulsion engine switched on 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 2Weizmann Institute scientists develop a unique approach for splitting water into hydrogen and oxygen 3
...ore tubes to 1 outflow Single-cell and patch deli...everal millisecond) solution change Very small de...on , Solid construction 360, 250 and 100 micro...ny micromanipulator Available in 4, 8, and 16 cha...
steadylite plus Reporter Gene Assay System, 100 mL from PerkinElmer
pTRI-GAPDH-Human (316 bp protected fragment) from Ambion
...nsect Medium is formuatled for the growth of insec... Insect Mediu, Unsupplemented is ideal for transfe...rosylate, and yeastolate, which can interfere with... is formulated for general growth and maintenance ...
Biology Products: